Arch Biopartners Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners Inc. has made a significant announcement regarding their Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the trial, adding to the excitement surrounding this groundbreaking study.

Dr. David Mazer, a translational researcher, anesthesiologist, and intensivist at St. Michael’s Hospital, expressed his enthusiasm for participating in the trial, highlighting the hospital’s commitment to investigating key mechanisms underlying tissue injury and healing. The clinical team at St. Michael’s Hospital is currently awaiting ethics approval before beginning enrollment in the trial.

With the addition of St. Michael’s Hospital as the third Canadian clinical site, the number of trial sites has now increased to nine, with six hospitals in Turkey actively recruiting patients. The international multi-center, randomized, double-blind, placebo-controlled study aims to recruit 240 patients and evaluate the percentage of subjects with AKI within seven days following on-pump cardiac surgery.

CS-AKI is a common complication in patients undergoing cardiac surgeries, with reported prevalence rates of up to 30%. The LSALT peptide targets the dipeptidase-1 (DPEP-1) pathway and has shown promising results in pre-clinical models, providing a strong scientific rationale for its use in the CS-AKI trial.

The Phase II trial, titled “Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery,” is a significant step forward in the development of new drug candidates that inhibit inflammation in the lungs, kidneys, and liver. The funding contribution from the National Research Council of Canada Industrial Research Assistance Program will help offset the costs of the trial.

This groundbreaking research has the potential to revolutionize the treatment and prevention of acute kidney injury in cardiac surgery patients, offering hope for improved outcomes and reduced morbidity and mortality rates. Stay tuned for more updates on this exciting development in the field of medical research.